JERSEY, Channel Islands , May 11, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland , and hVIVO, part of Open Orphan plc (LONDON:ORPH), today announced that the MosaiQ™ by Quotient system and MosaiQ COVID-19
JERSEY, Channel Islands , May 01, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced that it has completed the process for declaring conformity to the essential requirements of the In
JERSEY, Channel Islands , April 27, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today reported very strong final study performance data for its SARS-CoV-2 antibody test.
JERSEY, Channel Islands , April 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today reported positive performance data for its SARS-CoV-2 antibody test.
JERSEY, Channel Islands , April 06, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-19) antibody test
JERSEY, Channel Islands, March 13, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced the Company will host an investor information conference call and live webcast on March 25, 2020
JERSEY, Channel Islands , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological
Molecular Disease Screening Microarray Feasibility Study Completed Initial Serological Disease Screening FDA 510(k) Submission Accepted Commencement of EU Expanded Immunohematology Field Trial Activities Continued Strong Top Line Growth in the Quarter and Year to Date JERSEY, Channel Islands , Jan.
JERSEY, Channel Islands , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2019, will be released before market open on Thursday, January 30, 2020.
